Syncona-backed biotech launches in bid to shield heart cells from heart attacks
There have not been too many biotechs explicitly focused on cardiology.
While many have at least made some effort in the space, it is normally not as big of a focus as oncology, vaccines or gene therapy given the large investments traditionally required to run late-stage trials. But that could be changing: After the launch of UK biotech Kyttaro focusing solely on cardiology earlier in April, another biotech has set up shop in the British Isles.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
